DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene - PubMed (original) (raw)
DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene
A E Fujimura et al. Infect Immun. 2001 Sep.
Abstract
Immunization of BALB/c mice with a plasmid containing the gene for Trypanosoma cruzi trans-sialidase (TS) induced antibodies that inhibited TS enzymatic activity, CD4+ Th1 and CD8+ Tc1 cells, and protective immunity against infection. We used this model to obtain basic information on the requirement of CD4 or CD8 or B-cell epitopes for an effective DNA-induced immunity against T. cruzi infection. For that purpose, mice were immunized with plasmids containing DNA sequences encoding (i) the entire TS protein, (ii) the TS enzymatic domain, (iii) the TS CD4+ T-cell epitopes, (iv) the TS CD8+ T-cell epitope, or (v) TS CD4+ and CD8+ T-cell epitopes. Plasmids expressing the entire TS or its enzymatic domain elicited similar levels of TS-inhibitory antibodies, gamma interferon (IFN-gamma)-producing T cells, and protective immunity against infection. Although the plasmid expressing TS CD4 epitopes was immunogenic, its protective efficacy against experimental infection was limited. The plasmid expressing the CD8 epitope was poorly immunogenic and provided little protective immunity. The reason for the limited priming of CD8+ T cells was due to a requirement for CD4+ T cells. To circumvent this problem, a plasmid expressing both CD4+ and CD8+ T-cell epitopes was produced. This plasmid generated levels of IFN-gamma-producing T cells and protective immunity comparable to that of the plasmid expressing the entire catalytic domain of TS. Our observations suggest that plasmids expressing epitopes recognized by CD4+ and CD8+ T cells may have a better protective potential against infection with T. cruzi.
Figures
FIG. 1
Schematic view of the primary structure of T. cruzi TS.
FIG. 2
Immune responses of mice immunized with pcDNA3-TS and p154/13. BALB/c mice were immunized as described in detail in Materials and Methods with pcDNA3-TS (▴), p154/13 (■), or pcDNA3 (●). Fourteen days after the last immunization, blood samples were collected and the sera were assayed for the presence of antibodies to TS by ELISA using polystyrene wells coated with recombinant TS-cat (A), or for the presence of TS-inhibitory antibodies (B). The results represent the mean values obtained from eight mice ± the standard deviations (SD). Pooled spleen cells obtained from three mice immunized with pcDNA3-TS, p154/13, or pcDNA3 were expanded for 6 days in the presence of irradiated A20J-TS cells. (C) The expanded cells were restimulated in the presence of A20J-pcDNA3, A20J-TS, A20J cells, or A20J cells coated with 1 μM TS359-367 peptide (A20J-TS359–367). IFN-γ was estimated in supernatants collected after 18 h. Results are expressed as averages of triplicate cultures ± SD.
FIG. 3
Trypomastigote-induced parasitemia and mortality in mice immunized with pcDNA3-TS, p154/13, and pcDNA3. BALB/c mice were immunized with pcDNA3-TS, p154/13, or pcDNA3. Three weeks after the last immunization, mice were challenged i.p. with 6,500 bloodstream trypomastigotes. (A) Course of parasitemia, estimated as described in Materials and Methods. The results represent the mean values obtained from eight mice ± the standard deviations. At the peak of infection (day 7), the parasitemia of mice immunized with pcDNA3-TS or p154/13 was significantly lower than the parasitemia of control animals injected with pcDNA3 (p<0.001). (B) Kaplan-Meier curves for survival of eight mice immunized with the indicated plasmid(s). Statistically significant survival was observed in mice immunized with pcDNA3-TS or p154/13 compared to animals that received pcDNA3 (P < 0.05).
FIG. 4
Immune responses of mice immunized with p154/13 and pΔ154/13. BALB/c mice were immunized with p154/13, pΔ154/13, or pcDNA3. Fourteen days after the last immunization, blood samples were collected and the sera were assayed for the presence of antibodies to recombinant TS-cat by ELISA (A) or for the presence of TS-inhibitory antibodies (B). The results represent the mean value obtained from eight mice ± the standard deviations (SD). Pooled spleen cells obtained from three mice immunized with p154/13, pΔ154/13, or pcDNA3 were expanded for 6 days in the presence of irradiated A20J-TS cells. (C) The expanded cells were restimulated in the presence of A20J-pcDNA3, A20J-TS, A20J cells, or A20J cells coated with 1 μM TS359-367 peptide (A20J-TS359-367). IFN-γ was estimated in supernatants collected after 18 h. Results are expressed as averages of triplicate cultures ± SD.
FIG. 5
Trypomastigote-induced parasitemia and mortality in mice immunized with p154/13, pΔ154/13, and pcDNA3. BALB/c mice were immunized with p154/13, pΔ154/13, or pcDNA3. Three weeks after the last immunization, mice were challenged i.p., with 6,500 bloodstream trypomastigotes. (A) Course of infection, with the mean values obtained from eight mice ± the standard deviations. At the peak of infection (day 8), the parasitemia of mice immunized with each plasmid were compared. The results were as follows: (i) p154/13 versus pcDNA3, P < 0.001; (ii) p154/13 versus pΔ154/13, _P_ = 0.011; (iii) pΔ154/13 versus pcDNA3, _P_ > 0.05. (B) Kaplan-Meier curves for survival of eight mice immunized with the indicated plasmid. Statistically significant survival was observed in mice immunized with p154/13 compared to animals that received pΔ154/13 or pcDNA3 (P < 0.05). The number of mice immunized with pΔ154/13 or pcDNA3 that survived infection was not significantly different (_P_ > 0.05).
FIG. 6
Immune response, trypomastigote-induced parasitemia, and mortality of mice immunized with p154/13, pCD8-epitope, and pcDNA3. BALB/c mice were immunized with p154/13, pCD8-epitope, or pcDNA3. Fourteen days after the last immunization, pooled spleen cells obtained from three mice immunized with each plasmid were expanded for 6 days in the presence of irradiated A20J-TS cells. (A) The expanded cells were restimulated in the presence of A20J-pcDNA3, A20J-TS, A20J cells, or A20J cells coated with 1 μM peptide TS359-367 (A20J-TS359-367). IFN-γ was estimated in supernatants collected after 18 h. Results are expressed as averages of triplicate cultures ± the standards of deviation (SD). Three weeks after the last immunization, mice were challenged i.p. with 6,500 bloodstream trypomastigotes. (B) Course of infection, with mean values obtained from eight mice ± SD. At the peak of infection (day 7), the parasitemia of mice immunized with each plasmid was compared. The results were as follows: (i) p154/13 versus pcDNA3, P < 0.001; (ii) p154/13 versus pCD8-epitope, _P_ < 0.01; (iii) pCD8-epitope versus pcDNA3, _P_ < 0.01. (C) Kaplan-Meier curves for survival of eight mice immunized with the indicated plasmid. Statistically significant survival was observed in mice immunized with p154/13 compared to animals that received pCD8-epitope or pcDNA3 (_P_ < 0.05). The number of mice immunized with pCD8-epitope or pcDNA3 that survived infection was not significantly different (_P_ > 0.05).
FIG. 7
Depletion of CD4+ T cells significantly reduces TS-specific antibodies and IFN-γ-secreting CD4+ and CD8+ T cells induced by immunization with p154/13. BALB/c mice were treated for three consecutive days with anti-CD4, anti-CD8, or rat-IgG. One and 22 days later, these mice were immunized i.m. with 100 μg of p154/13. In parallel, control mice received 100 μg of pcDNA3. (A) Fourteen days after the last immunization, blood samples were collected and the sera were assayed for the presence of antibodies to recombinant TS-cat by ELISA The results represent the mean values obtained from four mice ± the standard deviations (SD). (B) Pooled spleen cells obtained from two mice immunized with p154/13 and treated with anti-CD4, anti-CD8, or rat-IgG were expanded for 6 days in the presence of irradiated A20J-TS cells. The expanded cells were restimulated in the presence of A20J-pcDNA3, A20J-TS, A20J cells, or A20J cells coated with 1 μM peptide TS359-367 (A20J-TS359-367). IFN-γ was estimated in supernatants collected after 18 h. Results are expressed as the average of triplicate cultures ± SD.
FIG. 8
Immune responses of mice immunized with p154/13 and pΔ154/13-CD8. BALB/c mice were immunized with p154/13, pΔ154/13-CD8, or pcDNA3. Fourteen days after the last immunization, blood samples were collected and the sera were assayed for the presence of antibodies to recombinant TS-cat by ELISA (A) or for the presence of TS-inhibitory antibodies (B). Results represent the mean values obtained from eight mice ± the standard deviations (SD). (C) Pooled spleen cells obtained from three mice immunized with p154/13, pΔ154/13-CD8, or pcDNA3 were expanded for 6 days in the presence of irradiated A20J-TS cells. The expanded cells were restimulated in the presence of A20J-pcDNA3, A20J-TS, A20J cells, or A20J cells coated with 1 μM TS359-367 peptide (A20J-TS359-367). IFN-γ was estimated in supernatants collected after 18 h. Results are expressed as the average of triplicate cultures ± SD.
FIG. 9
Trypomastigote-induced parasitemia and mortality in mice immunized with p154/13, pΔ154/13-CD8, and pcDNA3. BALB/c mice were immunized with p154/13, pΔ154/13-CD8, or pcDNA3. Three weeks after the last immunization, mice were challenged i.p. with 6,500 bloodstream trypomastigotes. (A) Course of infection and the mean values obtained from eight mice ± standard deviations. At the peak of infection (day 8). the parasitemia of mice immunized with each plasmid was compared. The results were as follows: (i) p154/13 versus pcDNA3, P < 0.001; (ii) p154/13 versus pΔ154/13-CD8, _P_ > 0.05; (iii) pΔ154/13-CD8 versus pcDNA3, P < 0.001. (B) Kaplan-Meier curves for survival of eight mice immunized with the indicated plasmid. Statistically significant survival was observed in mice immunized with p154/13 or pΔ154/13-CD8 compared to animals that received pcDNA3 (P < 0.01).
Similar articles
- Costimulatory Effects of an Immunodominant Parasite Antigen Paradoxically Prevent Induction of Optimal CD8 T Cell Protective Immunity.
Eickhoff CS, Zhang X, Vasconcelos JR, Motz RG, Sullivan NL, O'Shea K, Pozzi N, Gohara DW, Blase JR, Di Cera E, Hoft DF. Eickhoff CS, et al. PLoS Pathog. 2016 Sep 19;12(9):e1005896. doi: 10.1371/journal.ppat.1005896. eCollection 2016 Sep. PLoS Pathog. 2016. PMID: 27642757 Free PMC article. - Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene.
Rodrigues MM, Ribeirão M, Pereira-Chioccola V, Renia L, Costa F. Rodrigues MM, et al. Infect Immun. 1999 Aug;67(8):3855-63. doi: 10.1128/IAI.67.8.3855-3863.1999. Infect Immun. 1999. PMID: 10417149 Free PMC article. - Trans-sialidase delivered as a naked DNA vaccine elicits an immunological response similar to a Trypanosoma cruzi infection.
Costa F, Pereira-Chioccola VL, Ribeirão M, Schenkman S, Rodrigues MM. Costa F, et al. Braz J Med Biol Res. 1999 Feb;32(2):235-9. doi: 10.1590/s0100-879x1999000200013. Braz J Med Biol Res. 1999. PMID: 10347760 Review. - CD8+ T cells in Trypanosoma cruzi infection.
Tarleton RL. Tarleton RL. Semin Immunopathol. 2015 May;37(3):233-8. doi: 10.1007/s00281-015-0481-9. Epub 2015 Apr 29. Semin Immunopathol. 2015. PMID: 25921214 Free PMC article. Review.
Cited by
- Epitopes in the Glycosylphosphatidylinositol Attachment Signal Peptide of Trypanosoma cruzi Mucin Proteins Generate Robust but Delayed and Nonprotective CD8+ T Cell Responses.
Bunkofske ME, Perumal N, White B, Strauch EM, Tarleton R. Bunkofske ME, et al. J Immunol. 2023 Feb 15;210(4):420-430. doi: 10.4049/jimmunol.2200723. J Immunol. 2023. PMID: 36603035 Free PMC article. - Use of Leishmania major parasites expressing a recombinant Trypanosoma cruzi antigen as live vaccines against Chagas disease.
Cai CW, O'Shea A, Eickhoff CS, Guo H, Lewis WG, Beverley SM, Hoft DF. Cai CW, et al. Front Microbiol. 2022 Nov 29;13:1059115. doi: 10.3389/fmicb.2022.1059115. eCollection 2022. Front Microbiol. 2022. PMID: 36523834 Free PMC article. - Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection.
Bontempi I, Leal K, Prochetto E, Díaz G, Cabrera G, Bortolotti A, Morbidoni HR, Borsuk S, Dellagostin O, Marcipar I. Bontempi I, et al. Clin Exp Immunol. 2020 Sep;201(3):306-316. doi: 10.1111/cei.13469. Epub 2020 Jul 6. Clin Exp Immunol. 2020. PMID: 32464684 Free PMC article. - Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice.
de la Cruz JJ, Villanueva-Lizama L, Dzul-Huchim V, Ramírez-Sierra MJ, Martinez-Vega P, Rosado-Vallado M, Ortega-Lopez J, Flores-Pucheta CI, Gillespie P, Zhan B, Bottazzi ME, Hotez PJ, Dumonteil E. de la Cruz JJ, et al. Hum Vaccin Immunother. 2019;15(1):210-219. doi: 10.1080/21645515.2018.1520581. Epub 2018 Sep 21. Hum Vaccin Immunother. 2019. PMID: 30192702 Free PMC article. - Th17 Cells Are More Protective Than Th1 Cells Against the Intracellular Parasite Trypanosoma cruzi.
Cai CW, Blase JR, Zhang X, Eickhoff CS, Hoft DF. Cai CW, et al. PLoS Pathog. 2016 Oct 3;12(10):e1005902. doi: 10.1371/journal.ppat.1005902. eCollection 2016 Oct. PLoS Pathog. 2016. PMID: 27695083 Free PMC article.
References
- Aliberti J C, Machado F S, Souto J T, Campanelli A P, Teixeira M M, Gazzinelli R T, Silva J S. Beta-chemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi. Infect Immun. 1999;67:4819–4826. - PMC - PubMed
- An L L, Rodriguez F, Harkins S, Zhang J, Whitton J L. Quantitative and qualitative analyses of the immune responses induced by a multivalent minigene DNA vaccine. Vaccine. 2000;18:2132–2141. - PubMed
- Arnholdt A C V, Piuvezam M R, Russo D M, Lima A P C, Pedrosa R C, Reed S G, Scharfstein J. Analysis and partial epitope mapping of human T cell responses to Trypanosoma cruzi cysteinil proteinase. J Immunol. 1993;151:3171–3179. - PubMed
- Cornell K A, Bouwer H G, Hinrichs D J, Barry R A. Genetic immunization of mice against Listeria monocytogenes using plasmid DNA encoding listeriolysin O. J Immunol. 1999;163:322–329. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials